This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Hang on a second…

This CME Activity has expired and is no longer available for credit.

Managing and Reducing CV Risk in T2DM: An Overview

Managing and Reducing CV Risk in T2DM: An Overview

Format

Webcast

Time to Complete

45 minutes

Released

November 11, 2016

Expires

November 11, 2017
Add to Queue


Maximum Credits

0.75 / AMA PRA Category 1 CreditTM

Accredited Provider



This activity is provided by Forefront Collaborative.

Commercial Supporter

Supported by educational grants from Novo Nordisk, Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Program Description

The management of cardiovascular risk in patients with type 2 diabetes continues to evolve with changing guidelines and emerging data. This online lecture will provide a brief overview of the evidence-based recommendations for management of cardiovascular risk in patients with type 2 diabetes and will highlight the latest data on the long-term cardiovascular outcomes associated with the newest medications to treat type 2 diabetes, including incretin therapies and sodium glucose transporter-2 inhibitors.

Intended Audience

The target audience for this educational activity is cardiologists, endocrinologists, primary care clinicians, and other healthcare providers who treat patients and are interested in the primary prevention of cardiovascular disease in patients with diabetes.

Educational Objectives

Upon completion of the activity, participants should be able to:

  • Discuss the guideline recommendations for the management of cardiovascular risk factors in patients with diabetes
  • Summarize existing and emerging evidence of cardiovascular safety of diabetes medications

Fee Information

There is no fee for this educational activity.

Conflict Of Interest Disclosure Policy

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s).* For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

Faculty

Harold Bays, MD, FTOS, FACC, FACE, FNLA
Medical Director and President,
Louisville Metabolic and Atherosclerosis Research Center
Louisville, KY

Dr. Bays has received research grants from: Amarin Corporation, Amgen, Ardea Biosciences, Arisaph Pharmaceuticals, AstraZeneca, Bristol-Meyers Squibb, Catabasis Pharmaceuticals, CymaBay Therapeutics, Eisai, Elcelyx Therapeutics, Eli Lilly and Company, Esperion Therapeutics, Ferrer/Chiltern International, Gilead Sciences, GlaxoSmithKline, Hanmi Pharmaceutical, Hisun USA, Home Access Health Corporation, Janssen Pharmaceuticals, Inc., Johnson & Johnson, Kowa American Corporation, Merck & Co., Necktar, Novartis, Novo Nordisk, Omthera Pharmaceuticals, Orexigen Therapeutics, Pfizer, ProNova Solutions, Regeneron Pharmaceuticals, Roche, Sanofi, Takeda Pharmaceuticals U.S.A., and TimPharma LLC. He has consulted for: Alnylam Pharmaceuticals, Akcea Therapeutics, Amgen, AstraZeneca, Eli Lilly and Company, Ionis Pharmaceuticals (ISIS), Janssen Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co., Moderna Therapeutics, Novartis, Procter & Gamble, ProNova Solutions, Regeneron Pharmaceuticals, Sanofi, and Takeda Pharmaceuticals U.S.A. He has also been a speaker for: Amarin Corporation, Amgen, AstraZeneca, Eisai, Regeneron Pharmaceuticals, Sanofi, and Takeda Pharmaceuticals U.S.A.

Lawrence Blonde, MD, FACP, MACE
Director, Ochsner Diabetes Clinical Research Unit
Frank Riddick Diabetes Institute
Department of Endocrinology
Ochsner Medical Center
New Orleans, LA

Dr. Blonde has consulted for: AstraZeneca, GlaxoSmithKline, Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk, and Sanofi. He has been a part of the speaker’s bureau for: AstraZeneca, Janssen Pharmaceuticals, Inc., Novo Nordisk, and Sanofi. He has received grant and research support from: AstraZeneca, Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk, and Sanofi.

Yehuda Handelsman, MD, FACP, FACE, FNLA
Medical Director and Principal Investigator,
Metabolic Institute of America
Tarzana, CA

Dr. Handelsman has received research grants from: Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Esperion, Grifols, Hanmi Pharmaceutical, Intarcia Therapeutics, Inc., GlaxoSmithKline, Lexicon Pharmaceuticals, Inc., Merck & Co., Novo Nordisk, and Sanofi. He has consulted for: Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Novo Nordisk, Regeneron Pharmaceuticals, Inc., and Sanofi. He has been a part of the speaker’s bureau for: Amarin Corporation, Amgen, AstraZeneca, Boehringer Ingelheim-Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Novo Nordisk, Regeneron Pharmaceuticals, Inc., and Sanofi. He was the IP-President of the American College of Endrocrinology. He was the editor of the Journal of Diabetes.

Accredited Provider Disclosure

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

Christine Tebben and Stephanie Breslan, MS, of Forefront Collaborative have no financial relationships to disclose relative to the content of this CME activity.

CME Content Review

The content of this activity was independently peer reviewed. The reviewers of this activity have no relevant financial relationships to disclose.

Credit

0.75

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Forefront Collaborative designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity includes discussion of off-label uses of drugs.

Disclaimer

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.

Instructions

To obtain credit, a score of 70% on the posttest is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the posttest and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact Christine_Tebben@forefrontcollab.com.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue